Shigano Miyuki, Takasawa Hironao, Hamada Shuichi
Safety Assessment Department, Kashima Laboratories, LSIM Safety Institute Corporation, 14-1 Sunayama, Kamisu-shi, Ibaraki, 314-0255, Japan.
Bozo Research Center Inc, 1-3-11, Hanegi, Setagaya-ku, Tokyo, 156-0042, Japan.
Genes Environ. 2021 Sep 9;43(1):37. doi: 10.1186/s41021-021-00212-3.
The liver micronucleus (MN) assay is an effective and important in vivo test for detecting genotoxic compounds. In particular, the repeated-dose liver MN (RDLMN) assay which greatly facilitates incorporation of the liver MN assay into the general toxicity study has been developed. Usefulness of the RDLMN assay was appraised highly in the 7th International Workshops on Genotoxicity Testing (2017 in Tokyo) in that sufficient numbers and types of chemicals were studied and easy integration into the general toxicity study is preferred from the 3R's point of view. However, it was pointed out that it is necessary to evaluate the effect of age at the start of 4-week repeated administration, since there are limited data, where only those of rats of 6 week of age at the start of administration are available. In this study, we conducted the 4-week RDLMN assay using rats of 6 and 8 weeks of age (at the start of administration) to investigate the effect of age on the liver MN inducibility. Clofibrate, a weak inducer of liver MN, was used in this study to detect the slight difference in the liver MN induction.
The liver MN induced by clofibrate was detected in both rats of 6 and 8 weeks of age at the start of administration. However, the liver MN induction was lower in rats of 8 weeks of age compared to rats of 6 weeks of age at the start of administration.
These results suggest that the liver MN inducibility decreases with age. Therefore, we recommend the use of rats of 6 weeks of age at start of administration to reliably detect the liver MN induction in the RDLMN assay.
肝脏微核(MN)试验是检测遗传毒性化合物的一种有效且重要的体内试验。特别是,已经开发出了重复剂量肝脏微核(RDLMN)试验,该试验极大地促进了肝脏微核试验纳入一般毒性研究。在第七届遗传毒性测试国际研讨会(2017年于东京)上,RDLMN试验的实用性得到了高度评价,因为研究了足够数量和类型的化学物质,并且从3R原则的角度来看,将其轻松整合到一般毒性研究中是可取的。然而,有人指出,由于数据有限,仅提供了给药开始时6周龄大鼠的数据,因此有必要评估4周重复给药开始时年龄的影响。在本研究中,我们使用6周龄和8周龄(给药开始时)的大鼠进行了为期4周的RDLMN试验,以研究年龄对肝脏微核诱导性的影响。本研究使用氯贝丁酯(一种肝脏微核的弱诱导剂)来检测肝脏微核诱导的细微差异。
在给药开始时,6周龄和8周龄的大鼠中均检测到氯贝丁酯诱导的肝脏微核。然而,与给药开始时6周龄的大鼠相比,8周龄大鼠的肝脏微核诱导率较低。
这些结果表明,肝脏微核诱导性随年龄增长而降低。因此,我们建议在RDLMN试验中使用给药开始时6周龄的大鼠,以可靠地检测肝脏微核诱导情况。